Date: 2013-11-27
Type of information: Fundraising
Company: Bioaxial (France)
Investors: CEA Investissement (France), Inserm Transfert Initiative (France),
Amount: € 1.9 million
Funding type: equity investment
Planned used: This capital will back the commercial launch of Bioaxial’s first product, an optical microscopy module, which is expected in the second half of 2014. Bioaxial is developing imaging instruments for fluorescence microscopy that allow extended imaging of live cells with an improved resolution so far unreachable in research laboratories. This innovative module allows observation of living cells in super-resolution over time without damaging them, but unlike its competitors, does not require complex manipulations. It has been tested at the Institut Pasteur for the last 12 months. The founders of Bioaxial are experts in the industrialization of innovation and have an international track record in the semiconductor and optics industries.
Others: * On November 27, 2013, Bioaxial, a French developer of super-resolved fluorescence microscopy for the extended imaging of live cells, announced the completion of a € 1.9 million equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.
Bioaxial develops new technology for super-resolved fluorescence microscopy for extended imaging of live cells with a resolution of less than 100 nanometers. The optical modules manufactured by Bioaxial adapt as an add-on for commercial microscopes. Bioaxial has filed four patents and has acquired a fifth, all of which are held exclusively by the company. Bioaxial, founded in 2010, is headquartered in Paris and employs five people. It was founded by Gabriel Sirat and Louis-Philippe Braitbart who both trained as physicists and have international careers in the semiconductor and optical metrology industries.
Therapeutic area: Medical devices
